Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
398 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,681 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07461090 | Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis | recruiting | N/A | 60 | Menoufia UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma |
| recruiting |
| Phase 2 |
| 10 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT07223541 | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma(LAG-BOOST) | recruiting | Phase 2 | 72 | University of OklahomaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05641935 | Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation | recruiting | Phase 2 | 210 | john eisenbreyOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07386158 | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04623502 | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06583070 | SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer(COSTAR) | recruiting | — | 300 | Peking University First HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06234605 | A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 80 | HiberCell, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06726421 | Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)(STROKER) | recruiting | Phase 3 | 252 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT04299646 | A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases(GETUG-StORM-01) | recruiting | Phase 2 | 77 | Centre Francois BaclesseOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07326280 | The Cold Ischemia Robot-assisted Partial Nephrectomy | recruiting | N/A | 310 | Sun Yat-sen UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07301827 | Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma | recruiting | N/A | 66 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07171190 | Targeted Abdominal CT in Conjunction With Lung Cancer Screening(TACTICAL1) | recruiting | N/A | 6,272 | University of CambridgeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294859 | Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy | recruiting | — | 285 | Jinling Hospital, ChinaOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05917106 | Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) | recruiting | — | 450 | Jinling Hospital, ChinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06676527 | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma | recruiting | — | 39 | Jinling Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07240610 | Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma(AURICRE) | recruiting | — | 145 | Zhe ChenOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04974671 | Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04989959 | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 35 | Orhan Kemal OzOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05387863 | Decision Aid (DA) for Renal Patients | recruiting | N/A | 40 | NYU Langone HealthOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05287464 | International Multicentric Study ARON-1 | recruiting | — | 1,220 | Hospital of MacerataOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06601296 | Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer(SPARK) | recruiting | Phase 2 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06005818 | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)(MRD GATE RCC) | recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05931393 | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma(CABOLD) | recruiting | Phase 4 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07190638 | Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial(CORTEX) | recruiting | N/A | 80 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | recruiting | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07175480 | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk(Perfumer) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07166445 | Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT | recruiting | — | 1,000 | Peking University First HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06302569 | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma(REPRINT) | recruiting | Phase 2 | 23 | Giuseppe ProcopioOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06255223 | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | recruiting | Phase 2 | 35 | Jinling Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07118813 | Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment | recruiting | — | 400 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06642220 | Ablative Radioembolization of Renal Cell Carcinoma Trial(ARRCC) | recruiting | Phase 2 | 16 | Derek W. CoolOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06903312 | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.(ITALIC-RCC) | recruiting | Phase 4 | 409 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 11, 2026source: clinicaltrials